Table 2.
Variables | Time | Time effect* | |||||
---|---|---|---|---|---|---|---|
Baseline | 6 months | 12 months | 18 months | 24 months | Coefficient | P value | |
EPIC-26 sexual score (0–100)† | 61.4 ± 30.4 | 59.8 ± 33.0 | 60.2 ± 30.9 | 57.7 ± 31.4 | 53.9 ± 30.7 | −0.311 | 0.0014 |
MAX-PC total score (0–54)‡ | 9.8 ± 8.0 | 8.0 ± 8.2 | 7.9 ± 7.6 | 8.0 ± 8.2 | 7.6 ± 7.1 | −0.053 | 0.0287 |
Prostate cancer anxiety (0–33)§ | 5.6 ± 6.0 | 4.7 ± 6.0 | 3.9 ± 5.3 | 3.9 ± 5.9 | 3.8 ± 4.9 | −0.067 | <0.0001 |
PSA anxiety (0–9)¶ | 0.27 ± 0.72 | 0.33 ± 0.95 | 0.31 ± 0.87 | 0.34 ± 1.06 | 0.29 ± 0.85 | 0.001 | 0.8348 |
Fear of recurrence (0–12)** | 3.8 ± 3.1 | 2.9 ± 2.9 | 3.7 ± 3.8 | 3.7 ± 3.7 | 3.6 ± 3.8 | 0.008 | 0.6169 |
AUA-SI symptom score (0–35)†† | 6.9 ± 5.5 | 7.5 ± 5.6 | 7.3 ± 5.1 | 7.3 ± 5.5 | 7.7 ± 5.4 | 0.016 | 0.3183 |
Mixed-effects models.
Higher score indicates higher sexual function.
,†,‡,§,¶Higher score indicates greater anxiety.
Higher score indicates worse AUA-SI urological symptom.
EPIC-26 = Expanded Prostate Cancer Index Composite-26; MAX-PC = Memorial Anxiety Scale for Prostate Cancer; PSA = prostate-specific antigen; AUA-SI = American Urological Association-Symptom Index.